A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer

Gynecologic Oncology
C L EdwardsJ T Wharton

Abstract

From May 1978 until November 1980, 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine, Adriamycin, and cyclophosphamide (HAC) to a combination of melphalan and cis-platinum. Eleven patients were excluded from analysis and another 5 patients were excluded from response analysis. Of 153 patients evaluable for response, there were 47, or 30.7%, complete responders (all determined surgically), 6 partial responders, and 100 nonresponders. The response rate for the HAC group was 31% and for the melphalan-platinum group was 37.8%. The overall response rate was 34.6%. Residual tumor diameter (less than or greater than 2 cm) exerted a statistically significant effect on response--47.8 vs 24.4%. Of the 47 complete responders, 7, or 14.9%, have relapsed, with the median duration of remission of 44+ months. Of the 158 patients evaluable for survival, 90 patients have died, with a median survival time of 27.9 months (HAC = 26.4 months, melphalan-platinum = 29.6 months). Age, FIGO stage, histologic grade, and residual disease all exerted a significant effect on survival time. Second-line therapy in the treatment fa...Continue Reading

References

Feb 1, 1978·Cancer·N Einhorn
Mar 1, 1977·Gynecologic Oncology·C R StanhopeF Rutledge
Jul 28, 1977·The New England Journal of Medicine·R R ReimerR C Young
Mar 1, 1978·Obstetrics and Gynecology·M S PiverL E Blumenson
Sep 1, 1976·Cancer·J P SmithF Rutledge
Dec 1, 1972·Cancer·J P SmithJ T Wharton
Jun 1, 1968·Clinical Obstetrics and Gynecology·D G DeckerC E Johnson
Apr 1, 1983·Gynecologic Oncology·L J CopelandJ Herson
Jul 15, 1981·Cancer·J T Wharton, J Herson

❮ Previous
Next ❯

Citations

Jan 1, 1992·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·U Abel
Aug 1, 1995·Critical Reviews in Oncology/hematology·P J Hoskins
Feb 21, 1985·The New England Journal of Medicine·G S RichardsonJ H Nelson
Apr 1, 1990·British Journal of Obstetrics and Gynaecology·J MasdingA P Menday
Feb 24, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M O NicolettoUNKNOWN Goccne Group (Gruppo Oncologico Cooperativo Clinico Nord-est), Padua, Italy
Apr 1, 1984·American Journal of Obstetrics and Gynecology·J T WhartonF N Rutledge
Mar 1, 1989·Gynecologic Oncology·D M GershensonR S Freedman
Feb 15, 1990·International Journal of Cancer. Journal International Du Cancer·M SawadaK Endo
Sep 1, 1988·Gynecologic Oncology·K C PodratzT O Wilson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.